Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote
Executive Summary
Risk committee has joined nearly all opioid reviews over past few years but didn’t for AcelRx's sublingual product; Raeford Brown, the analgesic advisory committee chair who was unable to attend the meeting, voices his displeasure with the vote.
You may also be interested in...
COVID Vaccine Advisory Committee: Be Careful What You Wish For
The US FDA has promised to hold a public advisory committee review before authorizing or approving any COVID-19 vaccine candidates. What could possibly go wrong?
Dsuvia: A Dull US FDA Review Preceded The Controversial Approval
US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.
Opioids: FDA Actions May Silence Call For Moratorium On Approvals
Citizen petition seeks review of all marketed opioids; agency is considering whether new opioids should have comparative benefit over existing drugs.